Spontaneous Liver Rupture In A Patient With Peliosis Hepatis

Last Updated on Saturday, 12 December 2009 03:28 Written by Natural Health Team Saturday, 12 December 2009 03:28

Hemodynamic Therapeutics’ HTI-101 clinical study for treatment-resistant hypertension meets primary endpoint
Hemodynamic Therapeutics, Inc. (HTI), a portfolio company of Cato BioVentures, announces the successful completion of its initial Phase 2 clinical study of its lead compound (“HTI-101″), a patented low-dose small-molecule investigational therapy intended for patients with treatment-resistant hypertension.
Montana’s still thriving under pressure
Joe Montana has joined the national fight against high blood pressure. Working with drug manufacturer Novartis, Montana participates in programs designed to educate people about the dangers of high blood pressure (hypertension) and the options for treatment available to them.
Bayer: Phase II Trial For Riociguat Drug Successful
FRANKFURT -(Dow Jones)- German pharmaceuticals company Bayer AG (BAYN.XE) said Thursday it has successfully completed a first phase II trial with Bayer Schering Pharma’s drug Riociguat in pulmonary hypertension owing to interstitial lung disease.
Blurred Vision after Cardiac Catheterization
A 56-year-old woman with hypertension presented with a sudden onset of painless impaired vision in the right eye. On the previous day, she had undergone cardiac catheterization for evaluation of …
Spontaneous Liver Rupture In A Patient With Peliosis Hepatis
Peliosis hepatis (PH) is a rare pathological entity. PH varies from minimal asymptomatic lesions to larger massive lesions that may present with cholestasis, liver failure, portal hypertension, avascular mass lesion, or even spontaneous rupture. A research article published in the World Journal of Gastroenterology addresses this problem. The research team from Inha University School of Medicine …

Natural Health Information Finds:

« What Does Hypertension Do? | Holiday depression »